Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Jennifer R. Bellon, Nabihah Tayob, David D. Yang, Jordan Tralins, Chau T. Dang, Steven J. Isakoff, Michelle K. DeMeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop, Sara M. Tolaney
Topics & Concepts
Trastuzumab emtansineTrastuzumabMedicineOncologyAdjuvantPaclitaxelStage (stratigraphy)Internal medicineRandomized controlled trialToxicityBreast cancerChemotherapyCancerPaleontologyBiologyHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer Treatment and Pharmacology